DME

New molecule enhances effect of anti-VEGF therapy for DMEActivation of Tie2–as a result of subcutaneous administration of AKB-9778 (Aerpio Therapeutics) in combination with an anti-vascular endothelial growth factor (anti-VEGF) therapy–enhances the effect of an anti-VEGF drug on diabetic macular edema (DME).
Insights from anti-VEGF pivotal DME trialsAnalyses of data collected in the RISE/RIDE and VIVID/VISTA clinical trials provide important messages about the efficacy and safety of ranibizumab (Lucentis, Genentech) and aflibercept (Eylea, Regeneron) for treatment of diabetic macular edema (DME).
DAVE study found little benefit of anti-VEGF/PRP for DMEThe scientific community knows that vascular endothelial growth factor (VEGF) causes increased, vascular permeability, resulting in diabetic macular edema (DME) in the ischemic retina, but how to stop the VEGF drive remains the challenge.
Year-2 Protocol T data paints different scenario from year-1The Diabetic Retinopathy Clinical Research Network’s (DRCR.net) Protocol T—the first head-to-head-to-head comparison among aflibercept (Eylea, Renegeron Pharmaceuticals), ranibizumab (Lucentis, Genentech), and bevacizumab (Avastin, Genentech)—found in its first-year results that all three agents improved vision and reduced edema effectively.
Sustained-release corticosteroid implant improves, slows progression of diabetic retinopathySustained intraocular delivery of fluocinolone acetonide (FAc) using the FAc 0.19 mg intravitreal implant (Iluvien, Alimera Sciences) improves and slows progression of diabetic retinopathy (DR), according to findings of post-hoc analyses of data from the pivotal Fluocinolone Acetonide for Diabetic Macular Edema (FAME) trials.
Nailing intravitreal implant injections
Nailing intravitreal implant injectionsTreating diabetic macular edema (DME) has evolved from the ETDRS-style focal/grid laser being the standard of care since 1985 to the modern era of pharmacotherapy—with anti-vascular endothelial growth factor (VEGF) injections now taking center stage as primary treatment for most patients.
New concepts about macular edema emerge from modern imaging studiesVolume-rendered optical coherence tomography (OCT) imaging allows new insight into retinal vascular flow and morphological changes in eyes with macular edema (ME), and the information obtained is the basis for new ideas about the pathogenesis of ME and therapeutic intervention, according to Richard F. Spaide, MD, Vitreous Retina Macula Consultants of New York.
Data support adding suprachoroidal injection to anti-VEGF for RVOResults from the phase II TANZANITE clinical trial support further investigation of adding suprachoroidal triamcinolone acetonide to anti-vascular endothelial growth factor therapy for treatment-naïve retinal vein occlusion.
New biomarker may predict treatment response in DMEResearchers have identified a new biomarker they believe can be used as a predictor of vision change in patients with diabetic macular edema, either during the natural history of the disease or after undergoing anti-VEGF therapy. The biomarker is disorganization of the retinal inner layers, or DRIL.
  • 1
  • 2
var script= ' ';